1st Annual Tandem ASPHO/PBMTC Educational Mtg: New Frontiers in Pediatric AlloSCT

描述（由申请人提供）：我们计划于2013年4月在佛罗里达迈阿密凯悦酒店举办关于“儿科异基因干细胞移植（AlloSCT）新前沿”的ASPHO/PBMTC联合研讨会。2012年5月，我们在新奥尔良举行的第25届ASPHO年会上举办了一次ASPHO/PBMTC联合会议，获得了出色的评价。基于这一充满希望的开端，我们计划在2013年举办一整天的专题讨论会，重点关注儿科AlloSCT的新进展和前沿。自从最初观察到AlloSCT在患有恶性和非恶性血液疾病的儿科受者中的成功以来，已经过去了55年。这一领域的进展已经相当大，儿科血液学家/肿瘤学家经常面临是否将其患者转介进行异基因干细胞移植的决定。此外，儿科血液科医生/肿瘤科医生经常在AlloSCT后接收他们的患者，并需要照顾他们的急性和晚期影响。ASPHO/PBMTC联合会议为儿科干细胞移植医生和其他非干细胞移植儿科血液学家和肿瘤学家之间的对话、讨论和评论提供了一个独特的机会。尽管迄今为止取得了成功，但仍有一些问题没有得到回答，需要进一步进行严格的调查，就这一主题举行多学科和多国专题讨论会将在一定程度上促进这一调查。本次拟议会议的主要目标（简要）：1）介绍儿童ALL中AlloSCT的进展，重点关注微小残留病、合格性和新型免疫治疗前后; 2）强调非恶性血液病儿童和青少年替代异基因干细胞供体来源的新策略; 3）讨论AlloSCT后免疫重建的时机和促进免疫更快恢复的方法; 4）确定利用 儿童骨髓增生性疾病中的AlloSCT; 5）开发儿童AlloSCT后血液学并发症的诊断和治疗方法; 6）加强对儿童恶性和非恶性血液学疾病的新型细胞治疗方法的理解;以及7）讨论优化AlloSCT中的药物治疗。次要目的包括：1）促进该领域年轻研究者的教育、指导和领导; 2）加强与儿科血液学家/肿瘤学家和儿科干细胞移植医生的国内和国际交流与合作;和3）为这一独特领域的合作研究提供一个持续的平台。这次关于儿科AlloSCT新前沿的研讨会的结果将增加我们对基础的理解，这一独特领域的科学转化和临床状态提供了多学科对话，批评和合作研究的机会。这种教育机会也将弥合儿科血液学家和肿瘤学家之间的差距谁不积极从事儿科AlloSCT的艺术和科学，与那些医生科学家谁是全职活跃在儿科AlloSCT。

DESCRIPTION (provided by applicant): We plan to conduct a combined ASPHO/PBMTC symposia on "New Frontiers in Pediatric Allogeneic Stem Cell Transplantation (AlloSCT)" in April, 2013 at the Hyatt Regency Miami, Florida. In May 2012, we previously conducted a combined ASPHO/PBMTC session at the 25th Annual ASPHO meeting in New Orleans that received outstanding evaluations. Based on this promising beginning, for 2013 we plan a full day symposia focused on new advances and frontiers in pediatric AlloSCT. Over 55 years have passed since the original observations of the success of AlloSCT in pediatric recipients with both malignant and non-malignant blood disorders. The progress in this field has grown considerably and often Pediatric Hematologists/Oncologists are faced with decisions whether to refer their patients for an allogeneic stem cell transplant. In addition referring Pediatric Hematologists/Oncologists often receive their patients in return after an AlloSCT and need to care for their acute and late effects. The combined ASPHO/PBMTC venue offers a unique opportunity of dialogue, discussion and critique between pediatric stem cell transplantation physicians and other non-stem cell transplantation pediatric hematologists and oncologists. Despite the success to date, there are still a number of unanswered questions which require further critical investigations that would be facilitated in part by a multidisciplinary and multinational symposia on this subject matter. The primary objectives of this proposed conference (brief): 1) to present advances in AlloSCT in pediatric ALL with a focus on minimal residual disease, eligibility and novel pre and post immunotherapy; 2) to highlight new strategies in alternative allogeneic stem cell donor sources for children and adolescents with non-malignant hematological disorders; 3) to discuss timing of immune reconstitution after AlloSCT and methods of facilitating more rapid recovery of immunity; 4) to identify strategies of utilizing AlloSCT in pediatric myeloproliferative disorders; 5) to develop diagnostic and therapeutic approaches to hematological complications post pediatric AlloSCT; 6) to enhance the understanding of new novel cellular therapeutic approaches to pediatric malignant and non-malignant hematological disorders; and 7) to discuss optimizing drug therapy in AlloSCT. Secondary objectives include: 1) to promote education, mentoring and leadership of young investigators in the field; 2) to enhance national and international communication and collaboration with Pediatric Hematologists/Oncologists and Pediatric Stem Cell Transplantation physicians; and 3) to provide a continuing platform for collaborative research in this unique field The result of this symposia on New Frontiers in Pediatric AlloSCT will increase our understanding of the basic, translational and clinical state of the science in this unique field an provide an opportunity of multidisciplinary dialogue, critique and collaborative research. This educational opportunity will also bridge the gap between Pediatric Hematologists and Oncologists who are not actively engaged in the art and science of pediatric AlloSCT, with those physician-scientists who are full-time active in pediatric AlloSCT.